Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34
View Patent ↗The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
1. A method of inhibiting or reducing transplant rejection in a patient in need thereof, comprising
administering to the patient a therapeutically effective amount of an Interleukin-34 (IL-34) polypeptide.
2. The method according to claim 1 , wherein the transplant rejection is cardiac allotransplant rejection.
3. The method according to claim 1 , wherein the IL34 polypeptide has a sequence comprising of the sequence as set forth in SEQ ID NO: 1.
4. The method according to claim 1 , wherein the IL34 polypeptide has a sequence consisting of the sequence as set forth in SEQ ID NO: 1.
5. A method of inhibiting or treating of transplant rejection in a patient in need thereof, comprising
administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a IL-34 polypeptide.
6. The method according to claim 5 , wherein the IL34 polypeptide has a sequence comprising of the sequence as set forth in SEQ ID NO: 1.
7. The method according to claim 5 , wherein the IL34 polypeptide has a sequence consisting of the sequence as set forth in SEQ ID NO: 1.